Therapeutic potential of Sheng-Xian-Tang in doxorubicin-induced chronic heart failure by regulation of phenylalanine metabolism disruption
SXT mitigated DOX-induced CHF through hepatic PAH modulation. Neomangiferin could enhance PAH stability via competitive binding. Targeting PAH-phenylalanine metabolism emerged as a novel therapeutic strategy for DOX-induced cardiac dysfunction.
Authors
- Guangyang Jiao (ORCID: https://orcid.org/0000-0001-5486-032X)
- Xiangcheng Fan (ORCID: https://orcid.org/0000-0001-9563-9701)
- Mengqing Xiao
- Doudou Huang
- Zhimin Long
- Feng Zhang
- Chao Wang
- Wansheng Chen
- Lianna Sun
- Tao Pang
Institutions
- Second Military Medical University (CN)
- State Administration of Traditional Chinese Medicine of the People's Republic of China (CN)
- AbMax AntibodyChina (China) (CN)
- Tongde Hospital of Zhejiang Province (CN)
- Shanghai University of Traditional Chinese Medicine (CN)
- Hangzhou Hospital of Traditional Chinese Medicine (CN)
Publication Details
- Journal
- Chinese Medicine
- Published
- 2026-01-12
- DOI
- https://doi.org/10.1186/s13020-025-01316-6
- Citations
- 2
- Primary Topic
- Chemotherapy-induced cardiotoxicity and mitigation
- Type
- article
- Field-Weighted Citation Impact
- 60.13
Funders
- National Natural Science Foundation of China
- Chinese Pharmaceutical Association